Pro-Dex (PDEX) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
29 Jan, 2026Executive summary
Net sales for the quarter ended December 31, 2025, increased 11% year-over-year to $18.7 million, with six-month sales up 17% to $37.2 million, driven by strong growth in orthopedic and CMF device sales and next-generation handpiece shipments.
Net income for the quarter was $2.2 million, up 7% year-over-year, and $6.9 million for the six months, a 52% increase, reflecting higher sales and a significant realized gain on investment.
Gross margin for the quarter was 31%, up 1 percentage point year-over-year, while the six-month margin was 30%, down 2 points due to increased inventory and warranty charges and less favorable product mix.
Operating income rose to $3.3 million for the quarter and $6.4 million for the six months, reflecting improved sales and cost control.
Financial highlights
Orthopedic device sales rose 27% for the quarter and 43% for the six months, driven by the launch of a next-generation handpiece for the largest customer.
CMF device sales increased 69% for the quarter and 47% for the six months, while thoracic sales declined 83% and 67%, respectively.
Repair revenue declined 35% for the quarter and 30% for the six months due to fewer repairs of legacy products.
Realized a $6.8 million gain from the sale of Monogram Technologies shares following its acquisition by Zimmer Biomet, with a $3.2 million reversal of unrealized gains.
Cash and cash equivalents increased to $8.0 million at December 31, 2025, from $419,000 at June 30, 2025.
Outlook and guidance
Backlog at December 31, 2025, was $37.4 million, with $32.5 million scheduled for delivery in fiscal 2026.
Management expects continued growth in orthopedic sales for the remainder of the fiscal year and is pursuing the acquisition of a key supplier to meet demand.
A three-year contract extension with the largest customer is expected to support continued growth.
The company is focused on expanding manufacturing capacity and launching new products, including the Helios driver for CMF applications.
Latest events from Pro-Dex
- Shareholders to vote on director elections, auditor, executive pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Annual meeting seeks votes on directors, auditor, pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Revenue up 24% and net income quadrupled in fiscal 2025, with strong outlook for 2026.PDEX
Q4 20254 Sep 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025 - Sales and operating income rose sharply in 2024, but net income dropped on investment losses.PDEX
Q4 202413 Jun 2025